Various clinical and pre-clinical investigations have indicated that antagonists of the glucocorticoid receptor (GR) could be useful in the treatment of diabetes [1,2] and depression [3], but concerns about the effects of GR antagonists on the body's ability to regulate inflammatory responses [4] have hampered development of GR antagonists for these indications. Here, NR3C1 is linked to depressive disorder.